Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) General Counsel John R. Moore sold 20,922 shares of Edgewise Therapeutics stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $27.63, for a total transaction of $578,074.86. Following the completion of the sale, the general counsel now owns 3,252 shares of the company’s stock, valued at approximately $89,852.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Edgewise Therapeutics Stock Down 2.2 %
Shares of NASDAQ:EWTX traded down $0.57 during trading on Tuesday, hitting $25.92. 988,944 shares of the company traded hands, compared to its average volume of 961,431. The business’s fifty day moving average is $19.06 and its 200-day moving average is $18.20. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -16.72 and a beta of 0.15. Edgewise Therapeutics, Inc. has a one year low of $5.12 and a one year high of $30.00.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. On average, analysts forecast that Edgewise Therapeutics, Inc. will post -1.48 EPS for the current year.
Institutional Trading of Edgewise Therapeutics
Analyst Ratings Changes
Several research firms have recently weighed in on EWTX. Wedbush reissued an “outperform” rating and issued a $31.00 target price on shares of Edgewise Therapeutics in a research report on Friday, August 16th. Piper Sandler reissued an “overweight” rating and issued a $48.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 1st. Truist Financial increased their target price on Edgewise Therapeutics from $25.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. JPMorgan Chase & Co. boosted their price target on Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, August 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Edgewise Therapeutics in a report on Tuesday, September 17th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $35.00.
Check Out Our Latest Stock Report on EWTX
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Read More
- Five stocks we like better than Edgewise Therapeutics
- Options Trading – Understanding Strike Price
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Best Fintech Stocks for a Portfolio Boost
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.